TY - JOUR
T1 - Update on Retinal Vein Occlusion
AU - Romano, Francesco
AU - Lamanna, Francesca
AU - Gabrielle, Pierre Henry
AU - Teo, Kelvin Y. C.
AU - Parodi, Maurizio Battaglia
AU - Iacono, Pierluigi
AU - Fraser-Bell, Samantha
AU - Cornish, Elisa E.
AU - Nassisi, Marco
AU - Viola, Francesco
AU - Agarwal, Aniruddha
AU - Samanta, Anindya
AU - Chhablani, Jay
AU - Staurenghi, Giovanni
AU - Invernizzi, Alessandro
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Retinal vein occlusion represents the second leading cause of retinal vascular disorders, with a uniform sex distribution worldwide. A thorough evaluation of cardiovascular risk factors is required to correct possible comorbidities. The diagnosis and management of retinal vein occlusion have changed tremendously in the last 30 years, but the assessment of retinal ischemia at baseline and during follow-up examinations remains crucial. New imaging techniques have shed light on the pathophysiology of the disease and laser treatment, once the only therapeutic option, is now only one of the possible approaches with antivascular endothelial growth factors and steroid injections being preferred in most cases. Nowadays long-term outcomes are better than those achievable 20 years ago and yet, many new therapeutic options are under development, including new intravitreal drugs and gene therapy. Despite this, some cases still develop sight-threatening complications deserving a more aggressive (sometimes surgical) approach. The purpose of this comprehensive review is to reappraise some old but still valid concepts and to integrate them with new research and clinical data. The work will provide an overview of the disease's pathophysiology, natural history, and clinical features along with a detailed discussion on the advantages of multimodal imaging and of the different treatment strategies with the aim of providing retina specialists with the most updated knowledge in the field.
AB - Retinal vein occlusion represents the second leading cause of retinal vascular disorders, with a uniform sex distribution worldwide. A thorough evaluation of cardiovascular risk factors is required to correct possible comorbidities. The diagnosis and management of retinal vein occlusion have changed tremendously in the last 30 years, but the assessment of retinal ischemia at baseline and during follow-up examinations remains crucial. New imaging techniques have shed light on the pathophysiology of the disease and laser treatment, once the only therapeutic option, is now only one of the possible approaches with antivascular endothelial growth factors and steroid injections being preferred in most cases. Nowadays long-term outcomes are better than those achievable 20 years ago and yet, many new therapeutic options are under development, including new intravitreal drugs and gene therapy. Despite this, some cases still develop sight-threatening complications deserving a more aggressive (sometimes surgical) approach. The purpose of this comprehensive review is to reappraise some old but still valid concepts and to integrate them with new research and clinical data. The work will provide an overview of the disease's pathophysiology, natural history, and clinical features along with a detailed discussion on the advantages of multimodal imaging and of the different treatment strategies with the aim of providing retina specialists with the most updated knowledge in the field.
KW - BRVO
KW - CRVO
KW - review
KW - retinal vein occlusion
KW - update
KW - OPTICAL COHERENCE TOMOGRAPHY
KW - ENDOTHELIAL GROWTH-FACTOR
KW - MACULAR EDEMA SECONDARY
KW - PARS-PLANA VITRECTOMY
KW - LASER SCATTER PHOTOCOAGULATION
KW - PANRETINAL PHOTOCOAGULATION
KW - VITREOUS HEMORRHAGE
KW - NATURAL-HISTORY
KW - INTRAVITREAL TRIAMCINOLONE
KW - STANDARD-CARE
U2 - 10.1097/APO.0000000000000598
DO - 10.1097/APO.0000000000000598
M3 - (Systematic) Review article
C2 - 36912792
SN - 2162-0989
VL - 12
SP - 196
EP - 210
JO - Asia-Pacific Journal of Ophthalmology
JF - Asia-Pacific Journal of Ophthalmology
IS - 2
ER -